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Introduction
Approximately 100 000 new cases of multiple myeloma
(MM) are diagnosed each year worldwide (1), and MM
accounts for 1% of all cancer-related deaths (72 000
deaths annually) (1). Survival for patients with MM can
range from <6 months to more than 10 yr based on dis-
ease stage and prognostic factors (2). Clonal expansion
of malignant, terminally differentiated, B-lymphocyte–
derived plasma cells is characteristic of MM and typi-
cally results in excessive production of monoclonal im-
munoglobulins, thereby contributing to disruption of
immunologic activity and contributing to renal failure as
well as other complications, such as hyper viscosity (3,
4). Moreover, this neoplastic plasma cell expansion with
its attendant effects on the cytokine milieu disrupts
normal haematopoiesis (leading to anaemia) and skeletal
homoeostasis (resulting in extensive osteolytic lesions).
As a consequence, serum calcium levels may be elevated
and patients can develop debilitating skeletal-related
events (SREs; including pathologic fracture, spinal cord
compression and bone pain requiring surgery or pallia-
tive radiotherapy).
The severity of bone lesions and levels of haemoglo-
bin, serum calcium, serum creatinine, C-reactive protein
(CRP), serum albumin and b2-microglobulin (b2M) have
been identiﬁed as independent prognostic factors for sur-
vival in patients with MM, and have been incorporated
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International Staging Systems (ISS) (2). The widely used
ISS is a 3-stage classiﬁcation of MM that uses serum
b2M and albumin levels for prognostication. New
treatment options for MM have greatly improved sur-
vival rates, with median survival exceeding 5 yrs for
patients with ISS stage I disease (2), and reports of sur-
vival exceeding 10 yrs in some patients with advanced
disease undergoing stem-cell transplant and⁄or receiving
novel anti-myeloma regimens (2). However, outcomes
have typically been poor for patients with high-risk dis-
ease (e.g. median survival 6 months in patients with
high levels of CRP and b2M, vs. 54 months in patients
with low levels of these factors) (6) and, despite recent
therapeutic advances, the outlook for such patients
remains guarded.
Pathophysiology of myeloma bone disease
Myeloma-bone interactions typically result in increased
rates of osteoclast-mediated osteolysis, and myeloma
cells can secrete factors that inhibit osteoblast function
(osteogenesis) (7). Myeloma cells in the bone microenvi-
ronment typically secrete factors that interact with and
inﬂuence release of bone marrow-derived growth factors
and signalling intermediates, thereby rendering the bone
marrow even more conducive to myeloma growth, and
potentially setting up a cycle of osteolysis and myeloma
cell proliferation (7). In addition, myeloma cells also
stimulate secretion of receptor activator of nuclear fac-
tor-kappa B (NF-jB) ligand (RANKL) and inhibit
expression of osteoprotegerin (OPG; the decoy receptor
for RANKL) by osteoblasts, resulting in localised pro-
motion of bone resorption by osteoclasts to levels that
greatly exceed compensatory bone formation by osteo-
blasts which in turn are suppressed by humoral factors
such as dickkopf 1 (DKK1) (7). Consequently, bone
lesions from MM are highly destructive, and appear on
radiographs as purely lytic areas of ‘punched-out bone’,
which is quite different from the radiographic appear-
ance of osteolytic and sclerotic metastases from most
solid tumours. Low bone-mineral density and osteopo-
rotic fractures are also common among patients with
MM (8, 9) and may often be underdiagnosed, thereby
increasing the risk of extensive bone damage before
appropriate therapeutic intervention follows (8).
Supportive treatment for symptomatic disease
Symptomatic MM is typically characterised by elevated
serum calcium levels, renal deterioration, anaemia and
bone disease: a cluster of clinical manifestations often
referred to as CRAB criteria. Of these features, elevated
serum calcium and bone disease (speciﬁcally, SREs) are
readily addressed by therapeutic intervention with bis-
phosphonates (BPs). Over the last 15 yrs, the efﬁcacy of
BP therapy in preserving skeletal health and mitigating
SRE risk in patients with MM has been well established.
Accordingly, BPs have been incorporated as a supportive
therapy in patients with MM. Current American Society
of Clinical Oncology (ASCO) guidelines recommend
intervention with BP therapy for 2 yrs in patients with
MM with radiographic evidence of bone lysis or com-
pression fracture (10). The National Comprehensive Can-
cer Network (NCCN) recommendations are similar,
although they do not clearly specify the duration of BP
therapy (11). It should be noted that caution is advised
with use of BPs, given the incidence of certain complica-
tions, including osteonecrosis of the jaw (ONJ) (10).
Recently, newer agents have vastly improved clinical
outcomes for patients with symptomatic MM, and
although the treatment of MM has evolved in many
respects, the overall schema remains relatively
unchanged, although this may vary between the United
States and Europe (12) (Fig. 1). Patients with MM typi-
cally undergo one of two main treatment pathways based
on the feasibility and estimated beneﬁt of haematopoietic
stem cell transplant, although the necessity of this
approach in all younger patients is now an area of active
research. Although younger and ﬁtter patients with good
performance status are candidates for stem cell trans-
plant, older patients and those with poor performance
status may not derive beneﬁt. In both cases, patients typ-
ically receive systemic therapy consisting of an induc-
tion⁄consolidation and a maintenance phase. As
mentioned, supplementary BP therapy to preserve skele-
tal health is indicated for patients with symptomatic
MM and should be considered in all newly diagnosed
patients in whom there is no known contraindication.
Can bisphosphonates do more than strengthen
bone?
The development and progression of MM within the
bone are mediated by signalling of adhesion molecules
and the subsequent activation⁄secretion of cytokines and
growth factors that promote a destructive cycle of mye-
loma growth and bone loss (13). In BP-treated patients,
the drug is rapidly bound to the bone, where it is taken
up by both osteoclast and non-osteoclast cells, modifying
their function, intracellular interactions and cellular fate
(14). The coincident overlap of location and cellu-
lar⁄molecular components involved in MM and targeted
by BPs may disrupt or modify the interactions of mye-
loma cells with the bone microenvironment to inhibit
MM progression. Moreover, as BPs are rapidly cleared
from systemic circulation, they have minimal pharma-
cokinetic interaction with other therapies and may be
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been conﬁrmed in several studies (15). Certainly, both
preclinical and translational evidence supports potential
anti-myeloma effects of BPs; that is, increased host
immunity, overcoming resistance, and potential synergy
with other agents.
Preclinical data suggest single-agent anti-myeloma
activity for BPs (including zoledronic acid [ZOL]), as
well as at least additive activity with anti-myeloma
agents including thalidomide, dexamethasone and inter-
leukin-6 antagonists in MM models (16–22). In addition,
additive and⁄or synergistic activity has been reported
with combinations of ZOL and imatinib (23), hydroxy-
urea, cytarabine and daunorubicin (24) in leukaemia cell
lines. Preclinical models of MM also suggest that nitro-
gen-containing BPs (e.g. ZOL and pamidronate [PAM])
may induce myeloma cell apoptosis, inhibit disease pro-
gression and prolong survival (19, 22) speciﬁcally via
their inhibitory effects on the mevalonate pathway
(resulting in impaired protein prenylation, signalling and
consequently cell viability and function) (22). Some of
these preclinical mechanisms support observations from
translational and pilot studies. For example, in one
study, increased levels of apoptotic plasma cells were
detected in bone marrow aspirates from 14 of 16 patients
with newly diagnosed MM after a single infusion of
PAM (90 mg) (25). An added consequence of inhibiting
the mevalonate pathway is the accumulation of isopente-
nyl pyrophosphate (IPP), an intermediate implicated in
the activation and expansion of a subset of T cells
(Vc9Vd2; which exert anti-cancer immune activity) in
blood samples from MM patients (26). Potential anti-
myeloma effects of ZOL have also been reported in pilot
studies in patients with symptomatic (27), but not
smouldering MM (28). However, until recently, the clini-
cal beneﬁt of BPs had not been prospectively and sys-
tematically explored in patients with newly diagnosed
MM in both the stem cell transplant and non-stem cell
transplant settings.
The large, independent, randomised and prospectively
controlled Phase III MRC Myeloma IX trial compared
the relative efﬁcacy of zoledronic acid (ZOL) vs. clodro-
nate (CLO) (N = 1960) for reducing SREs and
improving disease-related outcomes across the prevailing
standard treatments in patients with newly diagnosed,
symptomatic MM (29). The primary efﬁcacy endpoints
assessed in this trial included progression-free survival,
overall response rate and overall survival (OS). Second-
ary endpoints included SRE incidence and toxicity.
Most patients had documented myeloma bone disease
(70%) at study entry. Zoledronic acid signiﬁcantly pro-
longed both progression-free survival and OS
(P = 0.0179 and P = 0.0118, respectively) vs. CLO.
Moreover, the OS curves showed an early (within
4 months) and sustained separation between the ZOL
and CLO arms, suggestive of beneﬁt to patients treated
with ZOL. Zoledronic acid also reduced the proportion
of patients with an SRE vs. CLO (27.0% vs. 35.3%,
respectively; P = 0.0004). It should be noted that the
improvement in OS was maintained after adjustment for
Figure 1 Treatment pathways in patients with newly diagnosed symptomatic multiple myeloma. SCT, stem cell transplant.
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suggesting that ZOL-mediated anti-myeloma effects
likely underlie the OS beneﬁt. Among patients allocated
to the non-intensive pathway, ZOL treatment
signiﬁcantly improved the complete or very-good-partial
response rate (P = 0.03) (29). In contrast, ZOL did not
signiﬁcantly improve the response rate in patients allo-
cated to the intensive pathway, perhaps because of the
higher overall response rate among patients undergoing
myeloablative therapy. Overall, the MRC Myeloma IX
study provides evidence for an anti-myeloma effect of
ZOL over and above that provided by CLO, which had
also previously demonstrated OS beneﬁt vs. placebo,
albeit restricted to the subset of patients without skeletal
fractures at presentation (30).
These data are concordant with previous clinical data
that suggest BPs may provide an anti-myeloma beneﬁt,
at least within certain subsets of patients. For example,
long-term treatment with intravenous PAM signiﬁcantly
increased survival in the subset of patients with MM
receiving second-line anti-myeloma therapy (n = 130; 14
vs. 21 months; P = 0.041) compared with placebo (31).
Similarly, in a retrospective analysis of 353 patients with
bone lesions with MM, ZOL treatment prolonged OS in
patients with high bone turnover (subset of patients with
high bone alkaline phosphatase levels, n = 89), com-
pared with PAM (32). More recently, Aviles et al. (27)
showed that combining ZOL with conventional chemo-
therapy in treatment-naive patients (N = 94) signiﬁ-
cantly improved 5-yr event-free survival (80% vs. 52%,
respectively) and 5-yr overall survival (80% vs. 46%,
respectively; P < 0.01 for both) compared with conven-
tional therapy alone. In contrast, the addition of PAM
to thalidomide for maintenance treatment of patients
with MM did not confer a survival advantage (33). How-
ever, in this study, PAM treatment may have been sub-
optimal, as suggested by the lack of signiﬁcant effect
observed on SRE incidence (P = 0.4).
The most recent Cochrane systematic review of BPs in
MM concluded that BP treatment was not associated
with improved survival among MM patients (34). Typi-
cally, in these types of analyses, effects on particular
patient subsets and activity of particular BPs may be
masked, and as noted by the authors, there was signiﬁ-
cant heterogeneity among these trials. It is also impor-
tant to note that this Cochrane analysis (34) pre-dates
the release of the MRC Myeloma IX data. Reﬂective of
this, an updated analysis by the same group, presented
at the American Society of Hematology annual meeting,
demonstrated superiority of ZOL over other BPs for
improving OS and potentially also preventing SREs in
patients with MM (35).
It should be noted that ZOL differs from early genera-
tion agents such as CLO in terms of both mechanism of
action and effectiveness in inhibiting bone resorption.
Newer-generation BPs such as ZOL are more effective
inhibitors of bone resorption and potentially are able to
demonstrate greater anti-myeloma activity (14, 15). In
addition, clinical data show that nitrogen-containing BPs
such as ZOL may inhibit tumour progression by enhancing
host anti-cancer immune response and inhibiting tumour-
mediated angiogenesis (15). Thus, it is perhaps not surpris-
ing that ZOL improved myeloma-related outcomes com-
pared with CLO in the MRC Myeloma IX study.
Overall, in the MRC Myeloma IX trial, ZOL was gen-
erally well tolerated with a small proportion of patients
(11–14%) still receiving BP after 4 yrs on study. Early
deaths (within the ﬁrst 4 months) attributed to infection
and renal failure occurred more frequently among
patients treated with CLO compared with ZOL. The
overall incidence of conﬁrmed ONJ among ZOL-treated
patients was signiﬁcantly higher than in patients treated
with CLO (3.6% vs. <1%, respectively; P < 0.001)
(29). Implementation of preventive measures, as done in
this trial, may reduce the incidence of ONJ (10). Interest-
ingly, there was no signiﬁcant difference in the incidence
of drug-related renal toxicity between study arms. Taken
together, the clinical beneﬁt provided by ZOL appears to
outweigh the risk of ONJ, especially if appropriate pre-
cautions are taken.
The MRC Myeloma IX trial has certain limitations.
The study was not prospectively designed to explore
translational endpoints (e.g. serum cytokine⁄growth fac-
tor levels) that might provide insights into the potential
anti-MM activity of ZOL. Such studies not only provide
proof of principle, but may also provide additional infor-
mation on future combinations of agents as treatment
regimens, and agents continue to evolve. Moreover,
although the survival beneﬁts from adding ZOL to the
standard therapies used in MRC Myeloma IX appeared
to be broadly independent of treatment pathway, current
bortezomib-based standards of care were not included in
this study, as the study preceded the emergence of this
key agent as a standard of care in the United Kingdom.
Existing data suggest a synergy between ZOL and bort-
ezomib in preventing bone resorption, including new
bone formation through osteoblast activation and inhib-
iting myeloma progression; their combination may there-
fore enhance clinical beneﬁt (36, 37).
Will the MRC Myeloma IX results alter treat-
ment guidelines for MM?
Overall, the results from MRC Myeloma IX support the
use of ZOL therapy in newly diagnosed MM patients
with early bone disease. In addition, these data support
previous observations from prior clinical studies sugges-
tive of survival beneﬁts from intravenous BP therapy
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anti-myeloma activity. Current ASCO and European
Myeloma Network guidelines recommend BP use in
patients with MM and evidence of bone disease (10, 38)
and are based exclusively on the bone-protective proper-
ties of BPs. The MRC Myeloma IX results now demon-
strate BP beneﬁts beyond bone protection—the reported
anti-myeloma beneﬁts of ZOL and possible bone-directed
(SRE-reduction) beneﬁts with initiating ZOL even before
the development of overt bone disease provide a rational
impetus to re-evaluate the role of BP therapy in patients
with newly diagnosed MM. Indeed, these results are
beginning to inﬂuence MM treatment guidelines. The
UK Myeloma Forum updated its guidelines in Septem-
ber 2010 to advocate BP therapy for all patients with
symptomatic MM regardless of bone lesion status and
supports the preferential use of ZOL in MM (39). More
recently, the NCCN amended its recommendations for
BP use to include ‘all patients receiving primary mye-
loma therapy’ (11). Moreover, a Canadian expert panel
issued a consensus statement in March 2011, supporting
ZOL as the BP of choice for the treatment of myeloma
bone disease and advocating further investigation into
the use of ZOL as an anti-myeloma agent in light of the
MRC Myeloma IX results (40).
It is notable that the earliest changes in BP recommen-
dations for MM following publication of the MRC Mye-
loma IX results have come from regions where CLO is
an established treatment option for patients with bone
lesions from MM. In many regions, including the United
States, PAM is extensively used to treat patients with
MM, and haematologists in these regions might question
whether the survival beneﬁts observed with ZOL vs.
CLO will be large enough to effect a change in treatment
practices or not (i.e. vs. PAM) (41). Nonetheless, the
MRC Myeloma IX results, together with ZOL effects
seen in conjunction with bortezomib and other novel
therapies (which may have independent effects on the
course of myeloma bone disease), may yet further
improve patient outcomes and provide an important
platform to counter the effects of MM on bone health
(15, 36, 37, 42).
Acknowledgements
We thank Katie Redman for administrative assistance and
Jerome F. Sah, PhD, ProEd Communications Inc.
 , for
writing assistance with this manuscript. This was sup-
ported in part by the Rick Corman Multiple Myeloma
Research Fund and Novartis Pharmaceuticals. All authors
were directly involved with this manuscript from inception
and writing of initial drafts, through multiple reviews⁄revi-
sions, to approval of the ﬁnal submitted version.
Conﬂict of Interest
PGR – Advisory Board: Celgene, Millennium, Novartis,
Johnson & Johnson, BMS. IMG – Advisory Board:
Celgene, Millennium, Novartis, Onyx. NR – Advisory
Board: Celgene, Novartis, Amgen, Research Funding:
AstraZeneca, Acetylon, Celgene. KCA – Advisory
Board: Novartis, Millennium, Celgene, Onyx, BMS,
Merck. Founder of Acetylon. JR – Research Funding:
Celgene, Millennium. AM – Advisory Board: Millen-
nium. JPL, RLS – have no competing interests.
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Par-
kin DM. Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–
917.
2. Greipp PR, San Miguel J, Durie BG, et al. International
staging system for multiple myeloma. J Clin Oncol
2005;23:3412–20.
3. Kumar SK, Mikhael JR, Buadi FK, et al. Management of
newly diagnosed symptomatic multiple myeloma: updated
Mayo Stratiﬁcation of Myeloma and Risk-Adapted Ther-
apy (mSMART) consensus guidelines. Mayo Clin Proc
2009;84:1095–110.
4. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging,
risk stratiﬁcation and response assessment of multiple
myeloma. Leukemia 2009;23:3–9.
5. Durie BG, Salmon SE. A clinical staging system for multi-
ple myeloma. Correlation of measured myeloma cell mass
with presenting clinical features, response to treatment,
and survival. Cancer 1975;36:842–54.
6. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-
reactive protein and beta-2 microglobulin produce a sim-
ple and powerful myeloma staging system. Blood
1992;80:733–7.
7. Terpos E, Dimopoulos MA. Myeloma bone disease: patho-
physiology and management. Ann Oncol 2005;16:1223–31.
8. Bouvard B, Royer M, Chappard D, Audran M, Hoppe E,
Legrand E. Monoclonal gammopathy of undetermined
signiﬁcance, multiple myeloma, and osteoporosis. Joint
Bone Spine 2010;77:120–4.
9. Edwards BJ, Langman CB, Bunta AD, Vicuna M, Favus
M. Secondary contributors to bone loss in osteoporosis
related hip fractures. Osteoporos Int 2008;19:991–9.
10. Kyle RA, Yee GC, Somerﬁeld MR, Flynn PJ, Halabi S,
Jagannath S, Orlowski RZ, Roodman DG, Twilde P,
Anderson K. American Society of Clinical Oncology 2007
clinical practice guideline update on the role of bisphosph-
onates in multiple myeloma. J Clin Oncol 2007;25:2464–72.
11. National Comprehensive Cancer Network. NCCN Clinical
Practice Guidelines in Oncology: Multiple Myeloma.
v.1.2012. Fort Washington, PA: National Comprehensive
Cancer Network Inc., 2011.
Richardson et al. Myeloma IX: changing treatment paradigms?
ª 2011 John Wiley & Sons A/S 512. Kyle RA, Rajkumar SV. Multiple myeloma. Blood
2008;111:2962–72.
13. Raab MS, Podar K, Breitkreutz I, Richardson PG,
Anderson KC. Multiple myeloma. Lancet 2009;374:324–
39.
14. Green J, Clezardin P. The molecular basis of bisphospho-
nate activity: a preclinical perspective. Semin Oncol
2010;37(Suppl 1):S3–11.
15. Neville-Webbe HL, Gnant M, Coleman RE. Potential
anticancer properties of bisphosphonates. Semin Oncol
2010;37(Suppl 1):S53–65.
16. Tassone P, Galea E, Forciniti S, Tagliaferri P, Venuta S.
The IL-6 receptor super-antagonist Sant7 enhances anti-
proliferative and apoptotic effects induced by dexametha-
sone and zoledronic acid on multiple myeloma cells. Int J
Oncol 2002;21:867–73.
17. Ural AU, Yilmaz MI, Avcu F, Pekel A, Zerman M, Nev-
ruz O, Sengul A, Yalcin A. The bisphosphonate zoledron-
ic acid induces cytotoxicity in human myeloma cell lines
with enhancing effects of dexamethasone and thalidomide.
Int J Hematol 2003;78:443–9.
18. Tassone P, Forciniti S, Galea E, Morrone G, Turco MC,
Martinelli V, Tagliaferri P, Venuta S. Growth inhibition
and synergistic induction of apoptosis by zoledronate and
dexamethasone in human myeloma cell lines. Leukemia
2000;14:841–4.
19. Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Ship-
man CM, Lippitt J, Green J, Van Marck E, Van Camp B,
Vanderkerken K. Zoledronic acid treatment of 5T2MM-
bearing mice inhibits the development of myeloma bone
disease: evidence for decreased osteolysis, tumor burden
and angiogenesis, and increased survival. J Bone Miner
Res 2003;18:482–92.
20. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y,
Epstein J. Myeloma interacts with the bone marrow
microenvironment to induce osteoclastogenesis and is
dependent on osteoclast activity. Br J Haematol
2002;116:278–90.
21. Avcu F, Ural AU, Yilmaz MI, Ozcan A, Ide T, Kurt B,
Yalcin A. The bisphosphonate zoledronic acid inhibits the
development of plasmacytoma induced in BALB⁄c mice
by intraperitoneal injection of pristane. Eur J Haematol
2005;74:496–500.
22. Guenther A, Gordon S, Tiemann M, Burger R, Bakker F,
Green JR, Baum W, Roelofs AJ, Rogers MJ, Gramatzki
M. The bisphosphonate zoledronic acid has antimyeloma
activity in vivo by inhibition of protein prenylation. Int J
Cancer 2010;126:239–46.
23. Segawa H, Kimura S, Kuroda J, et al. Zoledronate syn-
ergises with imatinib mesylate to inhibit Ph primary leu-
kaemic cell growth. Br J Haematol 2005;130:558–60.
24. Kimura S, Kuroda J, Segawa H, Sato K, Nogawa M, Yu-
asa T, Ottmann OG, Maekawa T. Antiproliferative efﬁ-
cacy of the third-generation bisphosphonate, zoledronic
acid, combined with other anticancer drugs in leukemic
cell lines. Int J Hematol 2004;79:37–43.
25. Gordon S, Helfrich MH, Sati HI, Greaves M, Ralston
SH, Culligan DJ, Soutar RL, Rogers MJ. Pamidronate
causes apoptosis of plasma cells in vivo in patients with
multiple myeloma. Br J Haematol 2002;119:475–83.
26. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP,
Wilhelm M. Stimulation of gammadelta T cells by amino-
bisphosphonates and induction of antiplasma cell activity
in multiple myeloma. Blood 2000;96:384–92.
27. Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S,
Huerta-Guzman J. Antitumor effect of zoledronic acid in
previously untreated patients with multiple myeloma. Med
Oncol 2007;24:227–30.
28. Musto P, Petrucci MT, Bringhen S, et al. A multicenter,
randomized clinical trial comparing zoledronic acid vs.
observation in patients with asymptomatic myeloma.
Cancer 2008;113:1588–95.
29. Morgan GJ, Davies FE, Gregory WM, et al. First-line
treatment with zoledronic acid as compared with clodronic
acid in multiple myeloma (MRC Myeloma IX): a rando-
mised controlled trial. Lancet 2010;376:1989–99.
30. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC,
Drayson MT. Long-term follow-up of a prospective,
double-blind, placebo-controlled randomized trial of
clodronate in multiple myeloma. Br J Haematol 2001;113:
1035–43.
31. Berenson JR, Lichtenstein A, Porter L, et al. Long-term
pamidronate treatment of advanced multiple myeloma
patients reduces skeletal events. Myeloma Aredia Study
Group. J Clin Oncol 1998;16:593–602.
32. Berenson J, Dimopoulos M, Chen Y-M. Improved sur-
vival in patients with multiple myeloma and high BALP
levels treated with zoledronic acid compared with pamid-
ronate: univariate and multivariate models of hazard
ratios. 48th ASH Annual Meeting and Exposition; 2006
December 9–12; Orlando, FL. Abstract 3589.
33. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance
therapy with thalidomide improves survival in patients
with multiple myeloma. Blood 2006;108:3289–94.
34. Mhaskar R, Redzepovic J, Wheatley K, Clark OA,
Miladinovic B, Glasmacher A, Kumar A, Djulbegovic
B. Bisphosphonates in multiple myeloma. Cochrane
Database Syst Rev 2010;3:CD003188.
35. Mhaskar R, Redzepovic J, Wheatley K, Clark O, Glasm-
acher A, Miladinovic B, Kumar A, Djulbegovic B. Com-
parative effectiveness of bisphoshonates in multiple
myeloma [ASH abstract]. Blood 2010;116:3028.
36. Moschetta M, Di Pietro G, Ria R, et al. Bortezomib and
zoledronic acid on angiogenic and vasculogenic activities
of bone marrow macrophages in patients with multiple
myeloma. Eur J Cancer 2010;46:420–9.
37. Terpos E, Christoulas D, Kokkoris P, Anargyrou K, Gav-
riatopoulou M, Migkou M, Tsionos K, Dimopoulos MA.
Increased bone mineral density in a subset of patients with
relapsed multiple myeloma who received the combination
of bortezomib, dexamethasone and zoledronic acid. Ann
Oncol 2010;21:1561–2.
Myeloma IX: changing treatment paradigms? Richardson et al.
6 ª 2011 John Wiley & Sons A/S38. Terpos E, Sezer O, Croucher PI, et al. The use of bis-
phosphonates in multiple myeloma: recommendations of
an expert panel on behalf of the European Myeloma Net-
work. Ann Oncol 2009;20:1303–17.
39. Bird J, Owen R, d’Sa S, Snowden J, Pratt G, Littlewood
T, Ashcroft J, Yong K, Cook G, Feyler S, Davies F,
Morgan G, Cavenagh J, Low E, Behrens J. Guidelines on
the Diagnosis and Management of Multiple Myeloma. Lon-
don: British Committee for Standards in Haematology in
conjunction with the UK Myeloma Forum [UKMF],
2010.
40. Reece D, Sebag M, White D, Song K. A Canadian
perspective on the use of bisphosphonates in the clinical
management of multiple myeloma. New Evidence in Oncol-
ogy. Published March 2011. Available at: http://www.
newevidence.com/oncology/pdfs/ccold-sup-march11_.pdf.
Accessed November 1, 2011.
41. Rajkumar SV. Zoledronic acid in myeloma: MRC
Myeloma IX. Lancet 2010;376:1965–6.
42. Richardson PG, Mitsiades C, Schlossman R, Munshi N,
Anderson K. New drugs for myeloma. Oncologist
2007;12:664–89.
Richardson et al. Myeloma IX: changing treatment paradigms?
ª 2011 John Wiley & Sons A/S 7